Long term imatinib treatment in pulmonary arterial hypertension [3]

Thorax

Volumn 61, Issue 8, 2006, Pages 736-

  Souza, R ^a   Sitbon, O ^a   Parent, F ^a   Simonneau, G ^a   Humbert, M ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CYTARABINE; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYUREA; IMATINIB; INTERFERON; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE;

ANEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; HUMAN; LETTER; LONG TERM CARE; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; PIPERAZINES; PYRIMIDINES;

EID: 33747041655     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2006.064097     Document Type: Letter

References (5)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
2. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-3.
3. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with First-line bosentan therapy in idiopamic pulmonary arterial hypertension. Eur Heart J 2006;27:589-95.
4. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21.
5. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.